Blocking NRP1 function produced a synergistic effect with that of anti VEGF, leading to inhibition of non-small-cell lung cancer (NSCLC) growth, which suggests that NRP1 may be a potential target for improving the efficacy of anti-VEGF therapy (12). The gene discussed is NRP1; the disease is non-small cell lung carcinoma.